Last Updated: August 8, 2026

Abbott Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ABBOTT

ABBOTT has one hundred and eleven approved drugs.



Summary for Abbott
US Patents:0
Tradenames:89
Ingredients:62
NDAs:111
Patent Litigation for Abbott: See patent lawsuits for Abbott

Drugs and US Patents for Abbott

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 019713-003 Sep 9, 1988 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 019506-001 Nov 7, 1986 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride CAPSULE;ORAL 061802-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott ERYTHROCIN erythromycin lactobionate INJECTABLE;INJECTION 062586-001 Jan 4, 1988 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 019118-001 Oct 11, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott DOPAMINE HYDROCHLORIDE dopamine hydrochloride INJECTABLE;INJECTION 070656-001 Jan 24, 1989 DISCN No No ⤷  Start Trial ⤷  Start Trial
Abbott AMINOSYN 3.5% IN PLASTIC CONTAINER amino acids INJECTABLE;INJECTION 018875-001 Aug 8, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbott

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-003 Dec 14, 1994 5,412,095 ⤷  Start Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-003 Dec 14, 1994 5,212,176 ⤷  Start Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-003 Aug 7, 1987 4,026,894 ⤷  Start Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-002 Dec 14, 1994 4,251,532 ⤷  Start Trial
Abbott PROSOM estazolam TABLET;ORAL 019080-002 Dec 26, 1990 3,987,052 ⤷  Start Trial
Abbott LOPURIN allopurinol TABLET;ORAL 018297-002 Approved Prior to Jan 1, 1982 3,624,205 ⤷  Start Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987 4,026,894 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ABBOTT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Capsules 10 mg and 15 mg ➤ Subscribe 2009-08-14
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.